NDS
Drug
Celgene Corporation
Total Payments
$495,135
Transactions
45
Doctors
17
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $271.25 | 4 | 3 |
| 2022 | $637.92 | 23 | 17 |
| 2021 | $68.81 | 1 | 0 |
| 2019 | $494,157 | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $494,157 | 17 | 99.8% |
| Long term medical supply or device loan | $977.98 | 28 | 0.2% |
Payments by Type
Research
$494,157
17 transactions
General
$977.98
28 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| USING REAL WORLD DATA TO CHANGE CHARACTERIZE PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE BEEN REFRACTORY TO MULTIPLE LINES OF TREATMENT WITH PRIOR EXPOSURE TO AN ANTI-CD38 ANTIBODY (NDS-MM-003) | Celgene Corporation | $333,001 | 0 |
| A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis (NDS-CP-001) | Celgene Corporation | $125,136 | 0 |
| An Observational Follow-on Study to Describe the Pharmacogenetics of the CC-90007-CP-003 Study Cohort (NDS-CP-003) | Celgene Corporation | $36,020 | 0 |
Top Doctors Receiving Payments for NDS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $494,862 | 22 |
| , RPA-C | Medical | Williamsville, NY | $50.98 | 3 |
| , MD | Family Medicine | Hamburg, NY | $50.98 | 3 |
| , MD | Family Medicine | Irving, NY | $50.98 | 3 |
| , M.D | Gastroenterology | Redlands, CA | $9.46 | 1 |
| , MD | Gastroenterology | Huntington Beach, CA | $9.46 | 1 |
| , M.D | Gastroenterology | Rancho Cucamonga, CA | $9.46 | 1 |
| , MD | Gastroenterology | Loma Linda, CA | $9.46 | 1 |
| , M.D | Gastroenterology | Santa Ana, CA | $9.46 | 1 |
| , M.D | Gastroenterology | West Hollywood, CA | $9.46 | 1 |
| Michael Jin | Diagnostic Radiology | Palo Alto, CA | $9.46 | 1 |
| , MD | Hepatology | San Bernardino, CA | $9.46 | 1 |
| , MD | Internal Medicine | Loma Linda, CA | $9.46 | 1 |
| , MD | Gastroenterology | Redlands, CA | $9.46 | 1 |
| , M.D | Internal Medicine | Loma Linda, CA | $9.46 | 1 |
| , MD | Gastroenterology | Banning, CA | $9.46 | 1 |
| , MD | Gastroenterology | Middletown, CT | $3.20 | 1 |
| , MD | Gastroenterology | Middletown, CT | $3.20 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $494,157
- PENTAX of America, Inc. $977.98
Product Information
- Type Drug
- Total Payments $495,135
- Total Doctors 17
- Transactions 45
About NDS
NDS is a drug associated with $495,135 in payments to 17 healthcare providers, recorded across 45 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2023. In 2023, $271.25 was paid across 4 transactions to 3 doctors.
The most common payment nature for NDS is "Unspecified" ($494,157, 99.8% of total).
NDS is associated with 3 research studies, including "USING REAL WORLD DATA TO CHANGE CHARACTERIZE PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE BEEN REFRACTORY TO MULTIPLE LINES OF TREATMENT WITH PRIOR EXPOSURE TO AN ANTI-CD38 ANTIBODY (NDS-MM-003)" ($333,001).